Business Wire

Clientron POS Terminal Won the Taiwan Excellence Award for the Fifth Consecutive Year 

Share

The 28th Taiwan Excellence Award ceremony was held in the afternoon of Nov. 27 in Taipei. Clientron, a smart retail IoT solution leading provider, won the jury's affirmation again with their "multi-functional integrated POS system" featuring innovative mechanism structure design, security, environmental protection and energy saving concepts. For the fifth consecutive year, Clientron has been selected through the jury’s rigorous review in the rating items of "Creative Innovation", "Product Design", "Manufacturing Quality", "International Marketing" and "Made in Taiwan ". This fifth consecutive award not only demonstrates Clientron's outstanding technology innovation but also proves their product design capabilities in optimizing user experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191203006119/en/

(Photo: Business Wire)

(Photo: Business Wire)

Clientron has been focused on product applications of smart retail trend and strives to help customers improve their operational efficiency with smart digital technology for many years. The award-winning PST650 series is a 15” 4:3 multi-function PCAP touch POS system with built-in printer, which is designed with high-performance & low-power platform and compliant with the latest ErP standard. The exquisite and beautiful dual color streamline chassis design can easily blend into the interior design aesthetics of various stores. Designed with a unique innovation and flexible foot stand, PST650 is compatible with various brands’ high-speed thermal receipt printers which are hidden in the foot stand. The innovative screwless mortise and tenon joint back cover design of the stand not only makes installation simple and maintenance easy, but also the flexible design allows for a variety of peripheral devices expansion on both sides of the screen. The whole system greatly improves cashier operation convenience and work efficiency by space-saving design and reducing external cable connection.

Kelly Wu, president & CEO of Clientron, said "The Taiwan Excellence Award has long been touted as the Oscars of Taiwan industry. It has been highly valued by Taiwan domestic and international companies. Winning the award for the fifth consecutive year is a great encouragement for all Clientron employees and also validates their long-term hard work. We are deeply grateful to all national jury members for affirming our innovative value and we also aspire to keep improving ourselves. This award-winning multi-functional integrated POS system has once again validated our R&D technology and the value of innovative design for the Smart Retail IoT application. We will keep on working hard to expand our global sales and marketing so the global buyers can see the true power of Taiwan's technology."

With the intensification of the IoT technology, Clientron will continue our efforts in the field of smart retail IoT applications to help customers solve the problems of "electronic payment", "safety of sales data transactions", " competitive market pressures ", and "corporate management needs." Clientron will provide smart retail solutions with variety and quality for the retail and hospitality industries to meet customers’ various service demands.

The PST650 Printer POS Terminal features highlight:

  • Embedded selectable 260 mm/sec High-Speed thermal printer
  • Easy access 2.5” HDD for installation and maintenance
  • 15” all-in-one panel PC style with bezel-free touch display
  • SII-RP-D10 and EPSON TM-m30 thermal printer compatible
  • IP64 water & dust- proof front panel protection
  • Power efficient Intel® Bay Trail J1900 2.0GHz processor
  • Optional VFD & 8”/9.7”/10.4” attached customer display
  • Optional MSR & iButton integrated at the side of the touchscreen

Please visit the company website at https://www.clientron.com/en/goods.php?act=view&no=55 for more product information.

About Clientron

Clientron was founded in 1983. The company is dedicated in providing global intelligent solutions to our clients. With design, manufacturing and service abilities, Clientron offers high-quality and high-performance computing platforms including Thin Client, POS, Automotive Electronics and Intelligent Systems. We commit to continuously provide better IoT client solutions and services for our partners and customers to build an intelligent e-World. Visit us at www.clientron.com .

Clientron Corp. http://www.clientorn.com

Contact information

Press Release Contact: Miss Hazel Yang
Email: hazel_yang@clientron.com
Tel: +886-2-26987068 #870

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom